Lixiana hits the mark in catheter ablation trialDaiichi Sankyo’s Lixiana was a late entrant to the novel oral anticoagulant (NOAC) category, but the Japanese drugmaker Share XLixiana hits the mark in catheter ablation trialhttps://pharmaphorum.com/news/lixiana-hits-the-mark-in-catheter-ablation-trial/
Apple Watch shows early promise in AFib diagnosisA large-scale study has provided some evidence that the Apple Watch could be used to detect atrial fibrillation Share XApple Watch shows early promise in AFib diagnosishttps://pharmaphorum.com/news/apple-watch-shows-early-promise-in-afib-diagnosis/
Keytruda bags another EU approval in frontline lung cancerMerck & Co/MSD has tightened its hold on the first-line lung cancer market with another EU approval for Share XKeytruda bags another EU approval in frontline lung cancerhttps://pharmaphorum.com/news/keytruda-eu-approval-lung-cancer/
UK gets early access to Roche’s breast cancer immunotherapyHard on the heels of an FDA approval for Roche’s Tecentriq and Celgene’s Abraxane for triple-negative breast cancer Share XUK gets early access to Roche’s breast cancer immunotherapyhttps://pharmaphorum.com/news/uk-early-access-roches-breast-cancer-immunotherapy/
Smith & Nephew buys Osiris in regenerative medicine pushMedical equipment company Smith & Nephew has agreed a $660 million deal to buy US biotech Osiris Therapeutics Share XSmith & Nephew buys Osiris in regenerative medicine pushhttps://pharmaphorum.com/news/smith-nephew-buys-osiris-regenerative-medicine/
NICE backs interim funding for J&J/Takeda myeloma regimenA three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be Share XNICE backs interim funding for J&J/Takeda myeloma regimenhttps://pharmaphorum.com/news/nice-backs-interim-funding-for-jj-takeda-myeloma-regimen/
Roche gets first checkpoint inhibitor OK in breast cancerRoche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to Share XRoche gets first checkpoint inhibitor OK in breast cancerhttps://pharmaphorum.com/news/roche-gets-first-checkpoint-inhibitor-ok-in-breast-cancer/
AbbVie/Roche seek first-line CLL use for Venclexta comboAbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new Share XAbbVie/Roche seek first-line CLL use for Venclexta combohttps://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/
Alnylam to seek approval for second RNAi drugAlnylam thinks it has strong enough clinical data for its gene-silencing drug for rare disease acute hepatic porphyria Share XAlnylam to seek approval for second RNAi drughttps://pharmaphorum.com/news/alnylam-approval-second-rnai-drug/
